Videos

Panelists review the previously presented patient case and discuss alternative treatment strategies in early disease progression with expert insight on preferred treatment approaches for this setting.

Expert oncologists discuss best practices surrounding treatment follow-up and monitoring for patients with relapsed or refractory follicular lymphoma.

Moaath Mustafa Ali, MD, MPH, reviews data on olverembatinib in patients with heavily pretreated/refractory chronic myeloid leukemia.

Resolving disparities within the blood cancer space is a matter of “access to excellent healthcare,” according to Usama Gergis, MD, MBA.

Expert perspectives on treatment considerations for ponatinib in patients with chronic myeloid leukemia.

Key opinion leaders detail strategies for patients with chronic lymphocytic leukemia relapsing after fixed-duration BTK and BCL2 inhibitor treatment, emphasizing the importance of genetic testing for mutations that could render them resistant to a re-challenge and considering third-generation BTK inhibitors if mutations are found.

Jack Khouri, MD, discusses phase 3 results from the CARTITUDE-4 study investigating ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

Following a review of data from the ALLIANCE A061202 study, experts on multiple myeloma discuss treatment considerations for patients being treated with ixazomib, pomalidomide, and dexamethasone.

Ricardo Parrondo, MD, discusses the potential of combining BTK and BCL2 inhibitors in chronic lymphocytic leukemia treatment, emphasizing their synergistic effect and cautioning against use in frail patients or those with cardiovascular comorbidities, while Pooja Advani, MBBS, MD, stresses the importance of medical history and risk stratification, especially regarding cardiovascular adverse effects.

A breast oncologist looks to the future of breast cancer treatment and discusses emerging therapies and ongoing clinical trials.

Expert perspectives on the treatment landscape for triple-negative breast cancer and the evolving role of immunotherapy in this space.

Concluding their comprehensive discussion on treating patients with multiple myeloma, the expert panel discusses unmet needs and looks to the future of treatment.

The panel presents the case of a 68-year-old man with multiple myeloma and offers their initial impressions.

Hypofractionated radiotherapy yields less financial toxicity than conventionally fractionated radiotherapy in patients with breast cancer who have undergone reconstruction following mastectomy.

Discrepancies in patients with blood cancer who are eligible for but do not undergo hematopoietic stem cell transplant have been observed not only for Black patients, but Hispanic, Asian, and White patients as well, according to Usama Gergis, MD, MBA.

Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.

Kristen Neumann, DNP, FNP-C, highlights the value of a multidisciplinary approach in the care of patients with EGFR-mutated non-small cell lung cancer, emphasizing the roles of dermatologists, pharmacists, and nurses in ensuring thorough patient assessment and education; Misako Nagasaka, MD, PhD, highlights data from WCLC 2023 on osimertinib in EGFR-mutated NSCLC.

Kristen Neumann, DNP, FNP-C, emphasizes the importance of early assessment and potential dose reductions or holds when patients on treatment for EGFR-mutated non-small cell lung cancer show adverse effects, while Misako Nagasaka, MD, PhD, stresses the need for accurate symptom history and supporting lab work to ensure patient safety.

Those with breast cancer who have undergone implant-based reconstruction following mastectomy have similar outcomes with hypofractionated vs conventionally fractionated radiotherapy.

Clinicians should not dismiss the concerns of younger patients who suspect they may have breast cancer, especially amid an increase in early-onset disease according to Monique Gary, DO, MSc, FACS.

Faculty highlight recent changes in treatment guidelines surrounding the use of PI3K inhibitors in follicular lymphoma and discuss the evolving role of these agents in the treatment landscape.

Hematologist/oncologists describe the rationale for treatment approaches targeting EZH2 and discuss recent guideline updates surrounding the role of tazemetostat and EZH2 testing in patients with follicular lymphoma.

Jay Yang, MD, reviews data from the OPTIC trial, a ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia.

A panel of experts on chronic myeloid leukemia from Karmanos Cancer Institute and Cleveland Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent data in the disease space.

Christina Wu, MB, BCh, MD, closes the program by expressing the necessity of enrolling patients with BRAF-mutant metastatic colorectal cancer in clinical trials, highlighting a second-line study led by the Southwest Oncology Group, new BRAF inhibitors, early phase studies at the Mayo Clinic, and an exciting study in the adjuvant setting.

Experts discuss that although first-generation BTK inhibitors such as ibrutinib were groundbreaking for CLL treatment, the field is now shifting toward second-generation options because of their better toxicity profiles. However, the choice between second-generation inhibitors should be personalized, considering individual patient profiles and adverse effects.

Andrew Kin, MD, reviews data on the addition of ixazomib to pomalidomide and dexamethasone in patients with multiple myeloma who progressed on lenalidomide in the first line.

Christina Wu, MB, BCh, MD, shares data from the phase 3 BREAKWATER trial, which assesses first-line targeted treatment strategies for patients with BRAF V600E-mutant metastatic colorectal cancer.

Experts highlight that second-generation BTK inhibitors offer improved toxicity profiles, lower cardiovascular risks, and are well tolerated for long-term CLL treatment.

A panel of experts on multiple myeloma from Karmanos Cancer Institute and Cleveland Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent data in multiple myeloma.